A newly-published White Paper, “A CEO’s Guide to Molecular Diagnostic Reimbursement: Navigating the Many Challenges of Reimbursement and Commercialization” covers everything from questions to consider when creating a business plan for commercialization of a genetic test to reimbursement options for molecular tests and coverage and contracting for molecular tests.
Given the infancy of molecular diagnostics, few CEOs have the prior experience to guide their companies to market while navigating the many hurdles of reimbursement and commercialization. With all of the challenges associated with running an early stage technology company, issues that involve future reimbursement seem distant and oftentimes are not a priority.
Some of the decisions that have to be made include balancing ease of market penetration, with leaving money and future revenue on the table; outsourced or in-house billing; contracted or non-contracted claims submission; client advocacy programs; and FDA clearance or laboratory developed test (CLIA). The good news is that a number of molecular diagnostic companies have perfected the formula and have turned into hyper-growth success stories that are shaping the future of diagnostics and health care.
The White Paper, will guide clinical laboratory owners and administrators on how to outsource their billing functions and then bring all or part of their billing services in-house over time without having to move their accounts receivable onto a new system.
Published by The Dark Report and Dark Daily, the White Paper is available free to laboratory professionals as a PDF download.
The paper’s author, Rina Wolf, has more than 20 years of experience in the diagnostic laboratory industry, specializing in molecular diagnostic laboratories. She is currently the Vice President of Commercialization Strategies, Consulting and Industry Affairs at XIFIN Inc.
Source: Dark Report
